Review



hybrid immunocapture lc ms ms  (KCAS Bioanalytical and Biomarker Services)


Bioz Verified Symbol KCAS Bioanalytical and Biomarker Services is a verified supplier
Bioz Manufacturer Symbol KCAS Bioanalytical and Biomarker Services manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    KCAS Bioanalytical and Biomarker Services hybrid immunocapture lc ms ms
    Hybrid Immunocapture Lc Ms Ms, supplied by KCAS Bioanalytical and Biomarker Services, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/Large+Molecule+Bioanalysis/pm40932638-220-7-10
    Average 93 stars, based on 1 article reviews
    hybrid immunocapture lc ms ms - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Biomarker Discovery:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Drug discovery:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    DNA Synthesis:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Imaging:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Clinical Proteomics:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Magnetic Resonance Imaging:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Diagnostic Assay:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Virus:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Neutralization:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Mass Spectrometry:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;

    Chromatography:

    Article Title: In Vivo Multimodal Self-Immolative Prodrug Nanomicelle-Hydrogel Modulate Key Intratumoral and Metastatic Genomic Signaling Pathways in Pancreatic Cancer
    Article Snippet: nomedicine has demonstrated numerically higher efficacy and safety compared to standard systemic free drug CT by overcoming some of these challenges, namely: (i) avoiding side and offtarget effects by active biomarker targeting or EPR at the site of interest; (ii) enhancing intracellular uptake in cancer and metastatic cells; (iii) improving controlled payload pharmacokinetics and pharmacodynamics;



    Similar Products

    retrogenix cell microarray  (Charles River Laboratories)
    86
    Charles River Laboratories retrogenix cell microarray
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Retrogenix Cell Microarray, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/pmc13276592-382-1-1
    Average 86 stars, based on 1 article reviews
    retrogenix cell microarray - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    retrogenix cell microarray 30  (Charles River Laboratories)
    86
    Charles River Laboratories retrogenix cell microarray 30
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Retrogenix Cell Microarray 30, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/10__1016_slash_j__isci__2026__116022-268-1-1
    Average 86 stars, based on 1 article reviews
    retrogenix cell microarray 30 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    retrogenix cell microarray technology  (Charles River Laboratories)
    86
    Charles River Laboratories retrogenix cell microarray technology
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Retrogenix Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/pmc12977278-382-14-18
    Average 86 stars, based on 1 article reviews
    retrogenix cell microarray technology - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    cell microarray technology screen  (Charles River Laboratories)
    86
    Charles River Laboratories cell microarray technology screen
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Cell Microarray Technology Screen, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/pm41742895-65-13-17
    Average 86 stars, based on 1 article reviews
    cell microarray technology screen - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    anti ccr8 antibodies retrogenix cell microarray technology  (Charles River Laboratories)
    86
    Charles River Laboratories anti ccr8 antibodies retrogenix cell microarray technology
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Anti Ccr8 Antibodies Retrogenix Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/10__1158_slash_1535___7163__mct___25___0367-84-5-7
    Average 86 stars, based on 1 article reviews
    anti ccr8 antibodies retrogenix cell microarray technology - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    retrogenix s cell microarray technology  (Charles River Laboratories)
    86
    Charles River Laboratories retrogenix s cell microarray technology
    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell <t>Microarray</t> Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
    Retrogenix S Cell Microarray Technology, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+microarray+assay/cell+microarray+screen+technology/us12435107-399-3-3
    Average 86 stars, based on 1 article reviews
    retrogenix s cell microarray technology - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell Microarray Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.

    Journal: iScience

    Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity

    doi: 10.1016/j.isci.2026.116022

    Figure Lengend Snippet: BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell Microarray Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.

    Article Snippet: The Retrogenix cell microarray was performed by Charles River Laboratories and included 6,105 full-length human proteins (plasma membrane proteins, secreted or a cell surface-tethered secreted proteins) and 400 human heterodimers.

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation, Microarray, Flow Cytometry, Transfection, Positive Control